Print

Oasmia Initiates Clinical Program With Paclical® in Metastatic Breast Cancer  
5/6/2013 9:18:59 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Uppsala, Sweden, 2013-05-06 14:00 CEST (GLOBE NEWSWIRE) -- The active substance of Paclical, paclitaxel, is used in the treatment of breast cancer, often in combination with e.g. hormonal treatment. Cytostatic treatment every third week has been clinical practice for an extended period of time. Adverse effects such as nausea and vomiting occur, but it is a significant decrease in the number of white blood cells that might lead to dose reduction and hence reduced effect of the treatment. The hypothesis is that weekly treatment with a lower dose would affect the white blood cells less than the tumour cells, thus provide a treatment with less adverse effect but with a maintained efficacy compared to 3-week treatment. Preliminary results showed that the treatment is well tolerated, and it was decided to initiate the program.

Help employers find you! Check out all the jobs and post your resume.

//-->